Atox Bio is a late stage biotechnology company that develops novel immunomodulators to treat critically ill patients. Initial focus is on patients with Necrotizing Soft Tissue Infections (“flesh eating bacteria”), a rare, life threatening, infection for which no current therapy exists. Reltecimod (AB103), the company’s lead product, is studied in ACCUTE (Reltecimod Clinical Composite endpoint Study in Necrotizing Soft Tissue Infections), a phase 3 clinical trial. Reltecimod received Orphan Drug designation from the FDA and EMA and Fast Track designation from the FDA.
Established in 2003 by Prof. Raymond Kaempfer and Dr. Gila Arad from the faculty of medicine at the Hebrew University, Atox Bio is a late stage biotechnology company that develops novel immunomodulators for critically ill patients.
Reltecimod, Atox Bio’s lead product, is initially being developed to treat Necrotizing Soft Tissue Infections (NSTI), a rare, life threatening infection with high morbidity and mortality.
Reltecimod is currently being studied in ACCUTE (Reltecimod Clinical Composite endpoint StUdy in necrotizing soft Tissue InfEctions) , a phase 3 clinical trial evaluating its efficacy in patient with NSTI. Previously, Reltecimod completed a phase 2 study in NSTI. Results demonstrated that patients treated with Reltecimod had a meaningful improvement across multiple end points.
Reltecimod was granted Fast Track status and Orphan Drug designation from the FDA as well as Orphan Medicinal Product designation from the European Commission.
Reltecimod development is supported by a contract from BARDA (Biomedical Advanced Research and Development Authority).
For more information please visit http://www.atoxbio.com
For more information about Atox Bio's Phase III study for necrotizing fasciitis (including a list of participating sites), visit here.
For more information about other ongoing or completed clinical trials for necrotizing fasciitis, visit here.